Microsoft (MSFT.US) launches new flagship laptop! Equipped with Nvidia chips, certain AI tasks outperform Apple MacBook.
Microsoft held a Surface product launch event on Wednesday, announcing the price and release schedule for the new flagship Surface Laptop Ultra equipped with Nvidia chips. Microsoft also stated that the device outperforms competing Apple products in certain artificial intelligence (AI) tasks.
According to Jinse Finance, Microsoft (MSFT.US) held a Surface new product launch event on Wednesday, announcing the price and release schedule of its new flagship laptop, the Surface Laptop Ultra, equipped with an NVIDIA (NVDA.US) chip. The company claims that its performance surpasses Apple’s (AAPL.US) competing products in certain artificial intelligence (AI) tasks.
According to Microsoft executives on Wednesday, the Surface Laptop Ultra can process prompts at twice the speed of Apple’s MacBook Pro M5 when running local AI models, and generates videos at six times the speed of similar Apple devices. The Surface Laptop Ultra is now available for pre-order and will begin shipping on October 16; the starting price is $2,599, which is about $400 less than the entry-level 16-inch MacBook Pro.
This brand-new Surface device is built on a NVIDIA chip designed for Windows laptops, which supports both general computing and AI computing. This also opens a new field of competition for NVIDIA with mainstream general PC processor manufacturers such as Intel (INTC.US) and AMD (AMD.US).
NVIDIA CEO Jensen Huang and Microsoft CEO Satya Nadella appeared together on stage to discuss the development of this new PC chip. Jensen Huang stated, “We have completely reinvented the personal computer.” Other Windows-based PC manufacturers such as Dell Technologies (DELL.US) and HP (HPQ.US) have also developed devices equipped with the new NVIDIA chip.
This is not Microsoft’s first attempt to boost device sales by leveraging the AI boom. In the summer of 2024, Microsoft and partners such as Qualcomm (QCOM.US) launched a massive marketing campaign around AI-optimized PCs. At the time, Microsoft promised that such devices would integrate AI features directly and achieve this with more powerful chips based on Arm Holdings (ARM.US) designs. However, the launch of this product line was hampered by privacy concerns related to one of its flagship features, which was originally intended to provide users with a helpful operating history of the device.
With Apple desktop computers experiencing a surge in demand in recent years due to their strong AI model performance, Microsoft is striving to maintain the dominant position of the Windows operating system in the AI era. According to research estimates, even though Microsoft Windows is the most popular PC operating system, the company does not rank among the world’s top six PC manufacturers by shipment volume.
As advances in AI and chip technology continue, tech giants including Microsoft, Apple, and Google (GOOGL.US) are working to enable users to run AI workloads more locally on their devices instead of relying on the cloud. Nadella stated that as time goes on, both developers and users will expect AI tools to draw computing power from both local hardware and cloud services.
In addition, during the event, Microsoft executives outlined the advantages of using Windows for AI-related work. Developers can leverage the computing power of the new devices without paying cloud provider fees, saving costs and enhancing security. They also highlighted Windows security features, which can be used to monitor and control AI agents’ behavior. The company also announced that Meta (META.US) will launch a Windows version of its popular Muse AI agent to capitalize on the soaring popularity of this personal assistant—which has already surpassed ChatGPT to top the Apple App Store charts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fed Governor Waller leaves room for hawkishness: More rate hikes are needed to support inflation decline, not necessarily on a monthly basis.
Federal Reserve Governor Waller stated that if the data meets expectations, there will be further interest rate hikes. The core PCE year-on-year rate at 3% is still too high, and the recent monetary policy focus remains on fighting inflation.
Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.
The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Oppenheimer Adjusts Acuity Price Target to $415 From $440, Maintains Outperform Rating
08:51 AM EDT, 10/08/2026 (MT Newswires) -- Acuity Brands (AYI) has an average rating of overweight and mean price target of $400.57, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
BUZZ-Pacira BioSciences stock surges on Viatris' $1.65 billion acquisition deal
On October 8, Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30 as Viatris (VTRS.O) announced it will acquire Pacira BioSciences for $1.65 billion in cash, at a price of $36.50 per share. This offer represents a premium of approximately 44.8% over Pacira's last closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris’ product portfolio. Both parties expect the deal to be completed by the end of 2026. As of the previous trading day’s close, PCRX was down 2.6% year-to-date.
Crypto prices
More
